

23. Belbin GM, Odgis J, Sorokin EP, et al. Genetic identification of a common collagen disease in Puerto Ricans via identity-by-descent mapping in a health system. *eLife*. 2017;6:6.
24. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. *Control Clin Trials*. 1998;19(1):61-109.
25. Trakadis YJ, Alfares A, Bodamer OA, et al. Update on transcobalamin deficiency: clinical presentation, treatment and outcome. *J Inherit Metab Dis*. 2014;37(3):461-473.

DOI 10.1182/blood-2018-03-841023

© 2018 by The American Society of Hematology

TO THE EDITOR:

Plerixafor effectively mobilizes CD56^{bright} NK cells in blood, providing an allograft predicted to protect against GVHD

Peggy P. C. Wong,^{1,2,*} Amina Kariminia,^{3,*} David Jones,⁴ Connie J. Eaves,⁵⁻⁷ Ronan Foley,^{8,9} Sabine Ivison,³ Stephen Couban,¹⁰ and Kirk R. Schultz¹⁻³

¹Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, BC Children's Hospital, Vancouver, BC, Canada; ²Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada; ³Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada; ⁴Department of Medicine, Memorial University, St. Johns, NL, Canada; ⁵Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada; ⁶Department of Medicine and ⁷Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada; ⁸Hamilton Health Sciences Centre, Hamilton, ON, Canada; ⁹Department of Medicine, McMaster University, Hamilton, ON, Canada; and ¹⁰Department of Medicine, Dalhousie University, Halifax, NS, Canada

The recent *Blood* article by Schroeder et al demonstrates that plerixafor mobilizes a unique hematopoietic stem and progenitor cell (HSPC) product that is enriched in plasmacytoid dendritic cell (pDC) precursors (pre-pDCs).¹ This study further reports that enrichment of these cells in plerixafor-mobilized allografts is associated with lower cumulative incidence of acute graft-versus-host disease (aGVHD) and chronic graft-versus-host disease (cGVHD). In an earlier study, Waller et al reported a protective advantage against aGVHD of pDCs derived from bone marrow (BM) but not granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood (PB) graft.² Studies have shown that allogeneic transplantation with a BM allograft results in lower rates of aGVHD and cGVHD when compared with G-CSF-mobilized PB graft. In a commentary to the Schroeder study, Waller proposes that the relatively rapid onset of mobilization by plerixafor (hours vs days by G-CSF) generates a novel PB graft that immunologically and phenotypically resembles cells harvested from bone marrow.³ He hypothesizes that this unique allograft contains immune subsets, including pre-pDCs and pDCs, which favorably modulate alloreactivity post-transplantation thus resulting in lower GVHD rates.

Recently, the Canadian Blood and Marrow Transplant Group (CBMTG) conducted a phase 3 randomized trial and compared the impact of G-CSF-mobilized PB to BM. In this trial, G-CSF-treated BM donors had a significantly lower frequency of cGVHD,⁴ similar to that seen in the Schroeder study. A further comprehensive investigation of the donor graft composition found that the lower rate of cGVHD in G-BM correlated most closely with a higher proportion of CD56^{bright} regulatory NK cells (NK_{reg}) represented as the percentage of CD56^{bright} NK_{reg} cells.⁵ Additional evidence of the importance of this immune-regulatory population is our recent observation of a correlation of low numbers of CXCR3⁺CD56^{bright} NK_{reg} cells with the onset of cGVHD in adults.⁶ Based on these observations, we hypothesized that an alternate donor cell population, with a selective increase in NK_{reg} cells by plerixafor, may contribute to the lower rate of cGVHD seen in the recent Schroeder study.

To address this possible mechanism, we recruited 9 healthy adult human volunteers after full consent. This study was approved by the Dalhousie University and University of British Columbia (UBC) research ethical boards. All subjects were between 18 and 60 years of age and were enrolled at the Dalhousie University. All biological analyses were performed at the UBC-affiliated BC Children's Hospital Research Institute. Five subjects received 1 dose of plerixafor at 240 µg/kg per day subcutaneously and PB and BM samples were harvested prior to administration and at 4 and 24 hours after plerixafor administration. The subsequent 4 participants each received 4 daily doses of G-CSF at 5 µg/kg per day for 4 days, followed by a dose of plerixafor on day 5. To minimize the impact of circadian rhythm, PB and BM samples were collected between 9 AM and noon, prior to G-CSF administration, after G-CSF completion, and at 4 and 24 hours after plerixafor administration. We performed a focused analysis on CD56^{bright} NK_{reg} cells in these samples using multiparametric flow cytometry. Nucleated cells isolated from peripheral blood and bone marrow samples were stained with CD3, CD8, perforin, granzyme B, CD56 antibodies conjugated to fluorescein isothiocyanate, phycoerythrin, PB, Flow-Check 770 fluorospheres, and allophycocyanin, respectively. Stained cells were acquired by LSR II cytometer (BD) and the data were analyzed by FlowJo v10. The immunophenotype of NK_{reg} cells is CD3⁻, CD56^{bright}, perforin⁻ and granzyme-B⁻.

Plerixafor significantly mobilized nucleated cells to PB after 4 hours of treatment, whereas no significant difference was observed after 24 hours of treatment (Figure 1A). Furthermore, longer treatment time resulted in a significantly lower cell number indicating that plerixafor's action peaked at 4 hours after administration. The magnitude of mobilization observed 4 hours after plerixafor administration was similar to that seen in the previous phase II clinical study.⁷ Interestingly, plerixafor did not alter the nucleated cell number in the bone marrow (Figure 1A). Four daily injections of G-CSF followed by plerixafor administration significantly mobilized more nucleated cells to PB than either treatment alone (Figure 1B). However, the two agents mobilized similar number of nucleated cells to PB separately. Therefore, plerixafor mobilized nucleated cells to peripheral blood more rapidly than G-CSF.




Figure 1. Effect of plerixafor and/or G-CSF administration on number of nucleated cells in peripheral blood and bone marrow. (A) Peripheral blood and bone marrow were harvested from 5 subjects prior to (baseline) and at 4 and 24 hours after administration of plerixafor (240 μ g/kg). Total nucleated cells were isolated from peripheral blood and bone marrow. Statistical significance was determined by the 2-tailed paired Student t test. (B) Peripheral blood was harvested from subjects (1) after 4-daily administration of G-CSF (5 μ g/kg); (2) after 4 hours of plerixafor (240 μ g/kg) administration; and (3) after 4-daily injections of G-CSF followed by plerixafor administration. Total nucleated cells were isolated from peripheral blood. Statistical significance was determined by the 2-tailed Student t test.

Since the peak action of plerixafor was seen at 4 hours after administration, we selected this time point for further analyses of plerixafor effect on CD56^{bright} NK_{reg} cells.


We next examined the effect of plerixafor on mobilizing CD56^{bright} NK_{reg} cells. Plerixafor induced a significantly higher rise of CD56^{bright} NK_{reg} cells in PB than 4 days of G-CSF alone or G-CSF followed by plerixafor (Figure 2A). This result suggested that plerixafor effectively mobilized CD56^{bright} NK_{reg} cells to the peripheral blood. Since the source of allograft influences risk of GVHD, we examined the effect of plerixafor on proportion of CD56^{bright} NK_{reg} cells in peripheral blood and bone marrow. We found a significant increase in proportion of CD56^{bright} NK_{reg} cells in PB relative to BM after plerixafor administration (Figure 2B). The CBMTG clinical trial demonstrates that G-CSF-mobilized bone marrow allograft associates with a lower incidence of GVHD compared with G-CSF-mobilized PB.⁴ Moreover, G-CSF mobilized bone marrow allograft that contains higher number of CD56^{bright} NK_{reg} cells is associated with lower frequency of GVHD.⁵ In this study, plerixafor effected a significantly larger increase in CD56^{bright} NK_{reg} cell population in PB than G-CSF stimulated BM allograft (Figure 2C). These results suggested that plerixafor mobilized the highest proportion of CD56^{bright} NK_{reg} cells to peripheral blood compared with bone marrow. One restriction

of this study is that we evaluated peripheral blood rather than a peripheral apheresis product and apheresis may alter graft composition.

Our group recently published the effect of plerixafor and G-CSF in mobilizing hematopoietic stem and progenitor cells (HSPCs) in the identical group as presented in this paper.⁸ In that publication, we demonstrated that plerixafor induces the greatest increase in CD34⁺ cells in peripheral blood (PB) 4 hours after drug administration with or without G-CSF. Notably, this is the exact time-point when plerixafor caused on the highest rise of CD56^{bright} NK_{reg} cell number in PB in this paper. In our previous publication, we evaluated the impact of plerixafor in PB using both three-week long-term in vitro culture and in an in vivo xenotransplant assays. We found that plerixafor optimally mobilizes hematopoietic populations to reconstitute neutrophils and platelets in transplanted immune deficient mice. Thus, plerixafor effectively mobilizes HSPC subsets with rapid myeloid repopulating capacity.

In addition to its efficacy in mobilizing HSPCs, we demonstrated in this study that a single subcutaneous administration of plerixafor effected the highest rise of CD56^{bright} NK_{reg} cell number in peripheral blood of healthy donors when compared with 4-daily G-CSF administration and G-CSF/plerixafor combination. In light

Figure 2. The effect of plerixafor and G-CSF on CD56^{bright} NK_{reg} populations in peripheral blood and bone marrow. (A) Number of CD56^{bright} NK_{reg} cells was enumerated from peripheral blood by flow cytometry. Fold change was computed as ratio between number of CD56^{bright} NK_{reg} cells after 4 hours of plerixafor administration, 4-daily administration of G-CSF (5 μg/kg), or 4-daily administration of G-CSF (5 μg/kg) followed by plerixafor administration and baseline. Statistical significant difference was determined by the 2-tailed Student t test. (B) Number of CD56^{bright} NK_{reg} cells was enumerated from blood and bone marrow by flow cytometry. Fold change was computed as ratio between number of CD56^{bright} NK_{reg} cells after 4 hours of plerixafor and baseline. Statistical significant difference was determined by the 2-tailed Student t test. (C) Number of CD56^{bright} NK_{reg} cells was enumerated from peripheral blood and bone marrow by flow cytometry. Fold change was computed as (1) ratio between number of CD56^{bright} NK_{reg} cells after 4 hours of plerixafor and baseline in peripheral blood; (2) ratio between number of CD56^{bright} NK_{reg} cells after 4-daily G-CSF administration and baseline in bone marrow. Statistical significant difference was determined by the 2-tailed Student t test.



of the recent observation that higher proportions of CD56^{bright} NK_{reg} cells in donor grafts significantly correlate with lower cGVHD rates,⁵ our findings suggest plerixafor would provide a PB donor product enriched in NK_{reg} cells and predicted to be protective against development of cGVHD. Indeed, Schroeder et al demonstrates that plerixafor-mobilized peripheral blood grafts result in lower incidence of acute and chronic GVHD when compared with G-CSF mobilized PB donor product.¹ We propose that future donor mobilization strategies should focus on enriching for

CD56^{bright} NK_{reg} cells, along with pre-pDCs and pDCs, in the donor product. We also suggest that the unique donor product mobilized by plerixafor is superior in minimizing cGVHD to G-CSF in allogeneic transplantation.

Acknowledgments

This work was supported by an unrestricted grant by Amgen (G-CSF), Genzyme, and the Division of Hematology, Dalhousie University.

Authorship

Contribution: P.P.C.W. analyzed and interpreted results, made figures, and wrote the paper; A.K. performed experiments and analyzed results; S.I. performed experiments; D.J., C.J.E., R.F., and S.C. designed research; and K.R.S. designed research and wrote the paper.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Kirk R. Schultz, Division of Pediatric Hematology/Oncology/Blood & Marrow Transplant, BC Children's Hospital, 4480 Oak St, Vancouver, BC V6H 3V4, Canada; e-mail: kschultz@mail.ubc.ca.

Footnote

*P.P.C.W and A.K. contributed equally to this study.

REFERENCES

1. Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. *Blood*. 2017;129(19):2680-2692.
2. Waller EK, Logan BR, Harris WA, et al. Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201. *J Clin Oncol*. 2014;32(22):2365-2372.
3. Waller EK. Mobilizing plasmacytoid dendritic cells. *Blood*. 2017;129(19):2600-2602.
4. Couban S, Aljurf M, Lachance S, et al. Filgrastim-stimulated bone marrow compared with filgrastim-mobilized peripheral blood in myeloablative sibling allografting for patients with hematologic malignancies: a randomized Canadian Blood and Marrow Transplant Group study [published correction appears in *Biol Blood Marrow Transplant*. 2017;23(3):534]. *Biol Blood Marrow Transplant*. 2016;22(8):1410-1415.
5. Kariminia A, Ivison S, Ng B, et al. CD56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. *Haematologica*. 2017;102(11):1936-1946.
6. Kariminia A, Holtan SG, Ivison S, et al. Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells. *Blood*. 2016;127(24):3082-3091.
7. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. *Blood*. 2008;112(4):990-998.
8. Miller PH, Nakamichi N, Knapp DJHF, et al. Quantitation of human cells that produce neutrophils and platelets in vivo obtained from normal donors treated with granulocyte colony-stimulating factor and/or plerixafor. *Biol Blood Marrow Transplant*. 2016;22(11):1945-1952.

DOI 10.1182/blood-2018-03-836700

© 2018 by The American Society of Hematology